LDH as a Biochemical Biomarker to Predict Organ Failure in the Emergency Department Setting

Completed

• Conditions: Multiple Organ Failure

• Registration Number: NCT01937676
• Lead Sponsor: Karolinska Institutet

Brief Summary

The purpose of this study is evaluate if K3, a novel biomarker, sampled at arrival to the emergency department can be used to predict the development of organ failure measured as SOFA score. K3 consists of lactate dehydrogenase, albumin and magnesium combined.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2013-08-30
• Study Start: 2013-09
• Study First Submitted QC: 2013-09-04
• Study First Posted: 2013-09-09
• Primary Completion: 2014-04
• Status Verified: 2016-09
• Last Update Submitted: 2016-09-03
• Last Update Posted: 2016-09-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1250

Inclusion Criteria

• Age ≥18 years
• Admitted to emergency department, Karlstad Central Hospital, Sweden

Exclusion Criteria

• Not in need of venous blood sample

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Development of multiple organ failure	30 days or complete ICU stay	Measured as SOFA score.

Secondary Outcome Measures

Name	Time	Method
All cause mortality	30 days after admission to emergency department
Cardiac function	30 days or complete ICU stay	Is it possible to predict cardiac function with the novel biomarker K3, which consists of lactate dehydrogenase, albumin, and magnesium combined?

Trial Locations

Locations (1)

Karlstad Central Hospital; 🇸🇪 Karlstad, Sweden